<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="199">
  <stage>Registered</stage>
  <submitdate>15/08/2005</submitdate>
  <approvaldate>17/08/2005</approvaldate>
  <actrnumber>ACTRN12605000170628</actrnumber>
  <trial_identification>
    <studytitle>Acute Stroke Treatment with Atorvastatin and Irbesartan</studytitle>
    <scientifictitle>A placebo controlled study to test the effectiveness of atorvastatin and irbesartan on infarct size, cerebral perfusion, cerebral response to ischaemia and clinical outcome in acute ischaemic stroke</scientifictitle>
    <utrn />
    <trialacronym>ASTART</trialacronym>
    <secondaryid>2004/085</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute Ischaemic Stroke</healthcondition>
    <conditioncode>
      <conditioncode1>Stroke</conditioncode1>
      <conditioncode2>Ischaemic</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>30 days Atorvastatina 80 mg and Irbesartan 150 mg 
2x2 factorial design</interventions>
    <comparator>Placebo - empty matching capsules daily for 30 days</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Infarct Size</outcome>
      <timepoint>At day 30</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Perfusion abnormality</outcome>
      <timepoint>At day 3</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Markers of inflammation and vascular function (CRP, vWF, fibrinogen, E selectin, plasma isoprostanes).</outcome>
      <timepoint>At day 3 and day 30</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Brain injury (S100B) and clinical outcome (MRS, MBS, NIHSS, MMSE).</outcome>
      <timepoint>At day 3 and day 30</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All patients admitted within 72 hours of onset of symptoms will be eligible for trial entry, unless exclusion criteria are met.If a person is unable to provide informed consent the next of kin will be sought to provide consent.  Patients regaining capacity will be free to continue in or withdraw from the trial. </inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Hypotension: Blood pressure less than 100mmHg systolic or 70mmHg diastolic.  Hypertension (&gt;220 mmHg) or clinical imperative to lower blood pressure. Hyperkalaemia: &gt;5.5 mmol/L. Finger prick or laboratory blood sugar level &gt; 13 mmol/L at baseline. Acute comorbid condition (such as myocardial ischaemia or sepsis). Active liver disease or unexplained elevation in transaminases. Already treated with ATRA, statin or more than one of an ACE inhibitor, non steroidal anti-inflammatory, potassium sparing diuretic, potassium salt or cyclosporin. Premenopausal female. Renal impairment (defined as creatinine &gt;120 umol/L). History of sensitivity to statins, ATRA or contrast. Haemorrhage seen on initial CT.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Concealed (randomisation table held by pharmacy)</concealment>
    <sequence>Computer generated random sequence stratified by time to event</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Factorial</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/05/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Western Australia</primarysponsorname>
    <primarysponsoraddress>Stirling Hwy CRAWLEY WA 6009</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Western Australia</fundingname>
      <fundingaddress>Stirling Hwy CRAWLEY WA 6009</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study aims to examine the effect of early treatment of acute ischaemic stroke with an ATRA and statin on surrogate markers of clinical outcome comprising the local response to ischaemia, cerebral blood flow, infarct growth and recurrent cardiovascular events.</summary>
    <trialwebsite />
    <publication>Beer C, Blacker D, Bynevelt M, Hankey GJ and Puddey IB. A Randomised Placebo Controlled Trial of Early Treatment of Acute Ischaemic Stroke with Atorvastatin and Irbesartan. Int J Stroke 2011; 7:104-111</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Christopher Beer</name>
      <address>Geriatric Medicine
University of Western Australia
Level 6 
Ainslie House
48 Murray St
Perth WA 6000</address>
      <phone>+61 8 92242750</phone>
      <fax>+61 8 92242063</fax>
      <email>cdbeer@graduate.uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Christopher Beer</name>
      <address>Geriatric Medicine
University of Western Australia
Level 6 
Ainslie House
48 Murray St
Perth WA 6000</address>
      <phone>+61 8 92242750</phone>
      <fax>+61 8 92242063</fax>
      <email>cdbeer@graduate.uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>